|
XOMA Corporation (XOMA): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
XOMA Corporation (XOMA) Bundle
In the cutting-edge world of biopharmaceutical innovation, XOMA Corporation emerges as a pivotal player in combating complex bacterial infections, strategically positioning itself at the intersection of groundbreaking scientific research and transformative therapeutic development. By leveraging proprietary antibody technologies and maintaining a laser-focused approach on infectious disease treatments, XOMA is redefining the landscape of medical innovation, offering investors and healthcare professionals a compelling glimpse into the future of targeted antibacterial therapies.
XOMA Corporation (XOMA) - Marketing Mix: Product
Biopharmaceutical Company Profile
XOMA Corporation is a biotechnology company focused on developing innovative antibacterial therapies with a specialized approach to therapeutic antibody development.
Product Portfolio
| Product Category | Description | Development Stage |
|---|---|---|
| Therapeutic Antibodies | Preclinical and clinical-stage antibacterial treatments | Ongoing research and development |
| Infectious Disease Treatments | Novel antibody-based therapeutic solutions | Multiple pipeline candidates |
Key Product Development Focus
- Preclinical antibacterial therapeutic research
- Clinical-stage infectious disease treatments
- Proprietary antibody discovery technologies
Technology Platform
Proprietary Antibody Discovery Technologies:
- Advanced antibody engineering capabilities
- Specialized bacterial infection targeting mechanisms
- Innovative therapeutic development approach
Pipeline Characteristics
| Pipeline Attribute | Specific Details |
|---|---|
| Primary Focus | Complex bacterial infection treatments |
| Development Approach | Targeted therapeutic antibody design |
Product Development Strategy
XOMA concentrates on developing specialized therapeutic antibodies with a primary emphasis on addressing challenging bacterial infection treatment scenarios.
XOMA Corporation (XOMA) - Marketing Mix: Place
Headquarters Location
2200 Powell Street, Suite 320, Emeryville, California 94608, United States
Global Research and Development Operations
| Location | Type of Operations |
|---|---|
| Berkeley, California | Primary Research and Development Center |
| Emeryville, California | Corporate Headquarters |
International Collaboration Network
- Pharmaceutical research partnerships in North America
- Collaborative research agreements with European research institutions
- Clinical trial networks across multiple continents
Distribution Channels
| Channel Type | Description |
|---|---|
| Direct Licensing | Pharmaceutical partnerships for drug development |
| Strategic Collaborations | Agreements with global pharmaceutical companies |
Market Targeting
Primary Markets: United States, European Union, Canada, Japan
Healthcare Sector Focus
- Infectious disease treatments
- Immunological research
- Rare disease therapeutic developments
Geographic Distribution
| Region | Market Presence |
|---|---|
| North America | Primary market (85% of research activities) |
| Europe | Secondary market (12% of research activities) |
| Asia-Pacific | Emerging market (3% of research activities) |
XOMA Corporation (XOMA) - Marketing Mix: Promotion
Conference Presentations
XOMA presents research findings at key medical and scientific conferences, including:
| Conference | Frequency | Typical Presentations |
|---|---|---|
| American Society of Clinical Oncology (ASCO) | Annual | Preclinical and clinical research updates |
| European Association for the Study of Diabetes (EASD) | Annual | Diabetes-related therapeutic research |
Investor Relations
XOMA conducts quarterly earnings calls with the following characteristics:
- Quarterly frequency
- Detailed financial performance reporting
- Management strategic outlook discussions
Scientific Publications
XOMA communicates research through peer-reviewed scientific journals:
| Publication Type | Number of Publications (2023) | Impact Areas |
|---|---|---|
| Peer-Reviewed Journals | 7-10 publications | Immunology, Oncology, Diabetes Research |
Digital Communication Platforms
XOMA maintains active digital communication channels:
- Corporate website with real-time updates
- LinkedIn corporate page
- Twitter account for scientific and corporate announcements
Media Communication Strategy
XOMA's media engagement includes:
| Communication Channel | Frequency | Purpose |
|---|---|---|
| Press Releases | 12-15 per year | Clinical trial results, corporate developments |
| Investor Press Conferences | 2-3 per year | Major research milestones and financial updates |
XOMA Corporation (XOMA) - Marketing Mix: Price
Stock Price and Financial Metrics
As of January 2024, XOMA Corporation's stock price trades on NASDAQ with the following key financial characteristics:
| Financial Metric | Value |
|---|---|
| Current Stock Price | $11.87 |
| Market Capitalization | $170.2 million |
| 52-Week Low | $8.45 |
| 52-Week High | $14.29 |
Pricing Strategy Components
XOMA's pricing strategy incorporates multiple revenue streams:
- Research collaboration payments
- Milestone-based licensing agreements
- Potential royalty revenues from therapeutic developments
Revenue Breakdown
| Revenue Source | 2023 Estimated Contribution |
|---|---|
| Research Collaborations | $12.6 million |
| Licensing Agreements | $5.3 million |
| Potential Royalties | Not yet realized |
Valuation Factors
Pricing influenced by:
- Clinical pipeline progression
- Potential therapeutic commercialization
- Intellectual property portfolio
Financial Performance Indicators
| Financial Metric | 2023 Value |
|---|---|
| Total Revenue | $17.9 million |
| Net Loss | $26.4 million |
| Cash and Equivalents | $89.6 million |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.